If you received the Johnson & Johnson Janssen COVID-19 vaccine, your risk of having a blood clot is very low, and that risk will decrease over time.

On April 13, the CDC and FDA recommended a pause in the use of Johnson & Johnson’s Janssen COVID-19 Vaccine. Of the nearly seven million doses administered so far in the United States, a small number of reports of a rare and severe type of blood clot have been reported in people after receiving the vaccine. All reports occurred among women between the ages of 18 and 48, and symptoms occurred six to 13 days after vaccination. As of April 13, of the more than 180 million doses administered so far of the Pfizer or Moderna vaccines, no reports matching those associated with the J&J/Janssen vaccine have been received.

Contact your healthcare provider and seek medical treatment urgently if you develop any of several symptoms:
• Severe headache;
• Backache;
• New neurologic symptoms;
• Severe abdominal pain;
• Shortness of breath;
• Leg swelling;
• Tiny red spots on the skin (petechiae); or
• New or easy bruising.

If you have any adverse events after vaccination, report them to v-safe at https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html?ACSTrackingID=USCDC_2067-DM55262&ACSTrackingLabel=What%20to%20Do%20If%20You%20Received%20the%20J%26J%2FJanssen%20COVID-19%20Vaccine%20%7C%20COVID-19&deliveryName=USCDC_2067-DM55262 and the Vaccine Adverse Event Reporting System at https://vaers.hhs.gov/reportevent.html?ACSTrackingID=USCDC_2067-DM55262&ACSTrackingLabel=What%20to%20Do%20If%20You%20Received%20the%20J%26J%2FJanssen%20COVID-19%20Vaccine%20%7C%20COVID-19&deliveryName=USCDC_2067-DM55262.